NGSX next targets: $0.80 then $1.05 gaps to fill $NGSX - Wedbush upgraded NeurogesX and raised its price target for shares to $2 from 50c citing the company's recently announced restructuring and renewed focus on liquid topical formulation NGX-1998. The firm sees limited downside risk at current share levels.